Asset profile
Zibotentan
Small molecule
Evidence outlook · lead readout
ZENITH-CKD (NCT04724837) · Chronic Kidney Disease
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
ZENITH-CKD (NCT04724837): Randomized, triple-blind, placebo-controlled phase 2 study with 447 participants in the analysis; the primary comparison (zibotentan 1.5 mg plus dapagliflozin vs dapagliflozin plus placebo) showed a statistically significant reduction in urinary albumin-to-creatinine ratio. Albuminuria is a regulator-accepted, disease-defining kidney endpoint, so the significant primary result in a well-designed controlled trial is strong evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 1 direct rival (same mechanism and indication), 3 same-class, 60 same-indication; 25 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zibotentan: this drug | Phase 3 | Small molecule | Endothelin A receptor | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Ambrisentan (Letairis) | Phase 3 | Small molecule | Endothelin A receptor | ||
| Zibotentan + Dapagliflozin | Phase 3 | Small molecule | Endothelin A receptor, SGLT2 | ||
| F230 | Phase 1 | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.